Current Opinion in Neurobiology最新文献

Empty clathrin cages in neurons. 神经元中空的网格蛋白笼。

IF 5.6 2区医学

Current Opinion in Neurobiology Pub Date : 2026-10-21 DOI: 10.1016/j.conb.2026.103285

Subhojit Roy

引用次数: 0

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-04-01 Epub Date: 2026-01-21 DOI: 10.1016/j.conb.2025.103163

Emmanuelle C. Genin , Véronique Paquis-Flucklinger

{"title":"ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies","authors":"Emmanuelle C. Genin , Véronique Paquis-Flucklinger","doi":"10.1016/j.conb.2025.103163","DOIUrl":"10.1016/j.conb.2025.103163","url":null,"abstract":"<div><div>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons. ALS often overlaps clinically and pathologically with frontotemporal dementia (FTD), the second most common form of dementia. Like many neurodegenerative disorders, both ALS and FTD share a crucial pathological hallmark, the aggregation of misfolded proteins into insoluble inclusions in degenerating neurons. This process is referred to as proteinopathy. This review focuses on the proteinopathies associated with ALS, including aggregates of TDP-43, SOD1, FUS, and CHCHD10, which disrupt critical cellular processes such as RNA metabolism, mitochondrial function, and protein homeostasis. The review highlights to the identification of new types of mitochondrial and cytosolic aggregates linked to <em>CHCHD10</em>-related ALS. Although the precise pathological mechanisms remain to be fully elucidated, strategies aimed at restoring proteostasis and reducing protein aggregation may be promising therapeutic approaches for treating ALS, as they directly target fundamental pathogenic mechanisms.</div></div>","PeriodicalId":10999,"journal":{"name":"Current Opinion in Neurobiology","volume":"97 ","pages":"Article 103163"},"PeriodicalIF":5.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146001741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease 实验药理学在确定帕金森病新疗法中的挑战

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-04-01 Epub Date: 2026-01-21 DOI: 10.1016/j.conb.2025.103164

Margaux Teil , Philippe Huot

{"title":"The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease","authors":"Margaux Teil , Philippe Huot","doi":"10.1016/j.conb.2025.103164","DOIUrl":"10.1016/j.conb.2025.103164","url":null,"abstract":"<div><div>An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.</div></div>","PeriodicalId":10999,"journal":{"name":"Current Opinion in Neurobiology","volume":"97 ","pages":"Article 103164"},"PeriodicalIF":5.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146001742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging the gap between physics and biology of hearing: Timing and amplification 弥合物理和听觉生物学之间的差距：时间和放大

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-13 DOI: 10.1016/j.conb.2025.103148

Christine Petit , Paul Avan

引用次数: 0

Sexually dimorphic neural circuits underlying mating behaviors: Insights from worms, flies, and mice 交配行为背后的两性二态神经回路：来自蠕虫、苍蝇和老鼠的见解。

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-23 DOI: 10.1016/j.conb.2025.103151

Xia-Jing Tong , Fei Wang , Xiaohong Xu

引用次数: 0

Corrigendum to “New insights into axonal regulators of dopamine transmission in health and disease” [Curr Op Neurobiol 94 (2025) 103093] “对健康和疾病中多巴胺传递轴突调节因子的新见解”的更正[Curr Op Neurobiol 94(2025) 103093]。

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-18 DOI: 10.1016/j.conb.2025.103147

Kathryn L. Todd , Kaitlyn M.L. Cramb , Katherine R. Brimblecombe , Stephanie J. Cragg

引用次数: 0

Editorial overview: Molecular neuroscience 编辑概述：分子神经科学。

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-17 DOI: 10.1016/j.conb.2025.103145

Yulong Li, Peter Scheiffele

引用次数: 0

Forward and backward prediction in learning and perception 学习和感知中的前向和后向预测。

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-10 DOI: 10.1016/j.conb.2025.103144

Floris P. de Lange , Clare Press

引用次数: 0

Gene therapy for Parkinson’s disease—Ample room for optimism 帕金森氏症的基因疗法——有足够的乐观空间

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-19 DOI: 10.1016/j.conb.2025.103150

Ivette M. Sandoval , Michael F. Salvatore , Fredric P. Manfredsson

{"title":"Gene therapy for Parkinson’s disease—Ample room for optimism","authors":"Ivette M. Sandoval , Michael F. Salvatore , Fredric P. Manfredsson","doi":"10.1016/j.conb.2025.103150","DOIUrl":"10.1016/j.conb.2025.103150","url":null,"abstract":"<div><div>The prospect of successful use of gene therapy to treat neurological disorders, including Parkinson’s disease (PD), can be increased by understanding the molecular etiology underlying disease symptoms and neurodegeneration. The major hurdle of safety for gene therapy use in central nervous system disorders has been cleared; with now ∼20 years since the first gene therapy clinical trial for PD, and with a large number of patients having received various treatments, the field has generated a large body of data with an impeccable safety record. As our understanding of the targetable components of disease processes evolves, so too do the tools available to target these processes. Viral vectors based on adeno-associated virus have undergone significant advancements in the last decade, including capsid improvements, enhanced production methods, and recombinant genome design. Although the etiopathology(ies) underlying PD is (are) yet to be defined, a number of therapeutic modalities with broad preclinical support have been, and are being, tested in humans. This includes proteins providing symptomatic relief, neuromodulation, monogenic correction, and neurotrophic support. The leading therapeutic gene therapy candidate has been glial cell line–derived neurotrophic factor (GDNF) or the closely related protein neurturin. Although clinical studies are still ongoing, recent work shows that protein levels of GDNF receptors (GDNF family receptor alpha1 and receptor tyrosine kinase) decrease with disease. Therefore, it is possible that optimal use of gene therapy using GDNF, and other protective pathways, can only be realized with an incisive assessment of all components of a targeted signaling pathway. Nevertheless, current clinical candidates, paired with a strong upcoming preclinical data pipeline, are setting the stage for an exciting future for PD gene therapy.</div></div>","PeriodicalId":10999,"journal":{"name":"Current Opinion in Neurobiology","volume":"96 ","pages":"Article 103150"},"PeriodicalIF":5.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145797662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of the social behavior network 社会行为网络的发展

IF 5.2 2区医学

Current Opinion in Neurobiology Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.conb.2025.103159

Nolwenn Adam, Jessica Tollkuhn

引用次数: 0